Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : BHV-8000
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Biohaven Pharmaceuticals
Deal Size : $970.0 million
Deal Type : Licensing Agreement
Details : Under the agreement, Biohaven and Highlightll will coordinate clinical development across global regions for BHV-8000 (previously TLL-041), an oral, brain-penetrant, dual inhibitor of TYK2 and JAK1 for the treatment of brain disorders.
Brand Name : BHV-8000
Molecule Type : Small molecule
Upfront Cash : $10.0 million
March 22, 2023
Lead Product(s) : BHV-8000
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Biohaven Pharmaceuticals
Deal Size : $970.0 million
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?
Reset All
